Gmax has built up an in-house antibody development platform which enables the antibody screening, humanization, and engineering, in order to obtain the antibody candidates with excellent drugability and developability.
GMAX Biopharm International raises USD 78M funding The financing will help revamp our clinical trials and develop pipeline candidates to produce more innovative medicines for global patients in a much faster speed. view allCONTACT US Investment: ir@gmaxbiopharm.com Clinical trials: clinical@gmaxbiopharm...
Technology Platform The Global First ETa-specific Monoclonal Antibody GMA131 was Approved by the US FDA for the Clinical Study of Diabetic Kidney Disease DKD, as the leading cause of chronic kidney disease and end stage renal disease (ESRD), is one of the most important complications of diabetes...
Gmax Biopharm International Limited is a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) therapeutic antibody and M-Body development, to address the unmet medical needs in cardiovascular diseases, metabolic disorders and cancer. Founded in 2010, GMAX has attracted...
CONTACT US WeChat Investment: ir@gmaxbiopharm.com Business Development: bd@gmaxbiopharm.com Clinical Trials: clinical@gmaxbiopharm.com Career: hr@gmaxbiopharm.com Copyright © 2017,Gmax Biopharm.All Rights Reserved. 浙ICP备11006114号-1
China Zhengzhou Gmax Biopharm LLC. C-3 Building Zhengzhou-Taiwan High Tech Park Xingang Street Zhengzhou Airport Economy Zone Zhengzhou, ChinaUS GenThera, Inc. 3254 Bordero Lane Thousand Oaks CA 91362 USA Australia Gmax Biopharm Australia Pty Ltd Suite 12.03, Level 12 50 Margaret Street Sydney ...
GMA301 - Endothelin receptor A/endothelin-1 axis is associated with pulmonary artery hypertension (PAH) and has been targeted for the treatment of PAH. GMA301 is a humanized monoclonal antibody against endothelin receptor A, may become the first long-lasting PAH drug with better efficacy and less...
2022年11月30日,Gmax Biopharm, LLC 下属的鸿运华宁(杭州)生物医药有限公司宣布,重组抗人 GLP-1 受体人源化单克隆抗体(GMA102)注射液用于二甲双胍治疗血糖控制不佳的2型糖尿病(T2DM)受试者III期临床研究完成首例受试者给药。 本研究是一项在二甲双胍单药治疗血糖控制不佳的2型糖尿病受试者中开展的为期52周的...
About Gmax Biopharm LLC: Gmax is a clinical stage company established in 2010 and headquartered inHangzhou, China. It’s a global company focusing on R&D, production and commercialization of antibody drugs targeting GPCRs. Gmax mainly works in cardiovascular, metabolic and cancer areas. Currently th...
www.gmaxbiopharm.com是鸿运华宁(杭州)生物医药有限公司旗下网站,网站成立于2010年12月3日,该网站属于综合其他行业。网站主要内容为:gmax biopharm llc.,gpcrs,gpcr mab discovery platform,monoclonal antibody development platform等。网站前端技术使用jquery,网站后端技术使用nginx。已开启GZIP压缩,用户主要来自土耳其,主要...